{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:33:11Z","timestamp":1758702791763},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,3,15]],"date-time":"2004-03-15T00:00:00Z","timestamp":1079308800000},"content-version":"vor","delay-in-days":43,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2004,2]]},"abstract":"<jats:p><jats:bold>Background and Objectives\u2002<\/jats:bold> Individuals with primary or secondary immune\u2010deficiency diseases may be at risk for vaccinia infection if widespread smallpox\u2010immunization programmes are implemented in the United States of America (USA) for bioterrorism preparedness. The objective of this study was to determine whether commercial immune globulin (intravenous, human) products contain biologically active antibodies to vaccinia that have the potential to protect people, with immune deficiencies, from complications of vaccinia.<\/jats:p><jats:p><jats:bold>Materials and Methods\u2002<\/jats:bold> Eight currently United States (US)\u2010licensed and two European intravenous immunoglobulin (IVIG) products were tested in a vaccinia plaque\u2010reduction neutralization assay. The <jats:italic>in vivo<\/jats:italic> activity of five of these lots was assessed in severely immune\u2010deficient mice.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> All tested products contained neutralizing anti\u2010vaccinia activity, <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> The use of IVIG by individuals with inherited or acquired humoral immune deficiencies may provide some protection if they are inadvertently exposed to vaccinia.<\/jats:p>","DOI":"10.1111\/j.0042-9007.2004.00397.x","type":"journal-article","created":{"date-parts":[[2004,3,15]],"date-time":"2004-03-15T16:06:55Z","timestamp":1079366815000},"page":"125-129","source":"Crossref","is-referenced-by-count":14,"title":["Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia"],"prefix":"10.1111","volume":"86","author":[{"given":"J. C.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Eller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mikolajczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Manischewitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Golding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. E.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,3,15]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"37","volume-title":"Intravenous Immunoglobulins in Clinical Practice","author":"Hooper JA","year":"1997"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(00)00297-1"},{"key":"e_1_2_6_4_2","first-page":"11","article-title":"Intravenous immune globulins: therapeutic, pharmaceutical and cost considerations","author":"Siegel J","year":"2001","journal-title":"Pharm Practice News"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199412000-00010"},{"key":"e_1_2_6_6_2","first-page":"341","article-title":": Recommendation of the Immunization Practices Advisory Committee Smallpox Vaccine","volume":"34","author":"Anon","year":"1985","journal-title":"MMWR"},{"issue":"07","key":"e_1_2_6_7_2","first-page":"1","article-title":": Recommendations for using smallpox vaccine in a pre\u2010event immunization program","volume":"52","author":"Wharton M","year":"2003","journal-title":"MMWR Recomm Rep"},{"issue":"10","key":"e_1_2_6_8_2","first-page":"1","article-title":": Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee for Immunization Practices, 2001","volume":"50","author":"Modlinand JF","year":"2001","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.26.2.176"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196911272812201"},{"key":"e_1_2_6_11_2","first-page":":308","volume-title":"Smallpox and its Eradication.","author":"Fenner F","year":"1988"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1542\/peds.18.2.177","article-title":"Hyperimmune vaccinial gamma globulin. Source, evaluation, and use in prophylaxis and therapy","volume":"18","author":"Kempe CH","year":"1956","journal-title":"Pediatrics"},{"key":"e_1_2_6_13_2","first-page":"689","article-title":"Responses to smallpox vaccine","volume":"347","author":"Frelinger JA","year":"2003","journal-title":"N Engl J Med"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm917"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/376557"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890410312"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(96)00163-6"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra022500"},{"key":"e_1_2_6_19_2","volume-title":"Vaccinia Immune Globulin Intravenous: Current Thinking and Indications for Use.","author":"Scott D","year":"2003"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.22.2127"},{"key":"e_1_2_6_21_2","first-page":"2791","volume-title":"Textbook of Pediatric Infectious Disease","author":"Stiehm ER","year":"1997"},{"key":"e_1_2_6_22_2","volume-title":"Package Insert for Vaccinia Immune Globulin, 1991","author":"Baxter Corporation:","year":"1991"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-83-12-2915"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-13-1-9"},{"key":"e_1_2_6_25_2","first-page":"86","article-title":"Differences between extracellular and intracellular forms of poxviruses and their implications","volume":"16","author":"Boulter EA","year":"1973","journal-title":"Prog Med Virol"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0042-9007.2004.00397.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0042-9007.2004.00397.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T20:29:31Z","timestamp":1696883371000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0042-9007.2004.00397.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["10.1111\/j.0042-9007.2004.00397.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0042-9007.2004.00397.x","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}